AID is increasingly incorporated into clinical practice to improve daily glycemic outcomes in T1DM. A nationwide observational study published in Diabetes, Obesity and Metabolism evaluated the 12-month effectiveness of AID across 79 clinical centers.

The cohort included 2,741 individuals with T1DM who initiated AID between January and December 2022. Median age was 38 years, median body mass index (BMI) was 24.5 kg/m², and median diabetes duration was 19 years. Devices included MiniMed 780G in 49.7%, Tandem Control-IQ in 49.3%, and other systems in 1%. Clinical measures and continuous glucose monitoring (CGM) metrics were collected at baseline and at 3, 6, and 12 months. The primary endpoint was change in TIR (3.9 to 10 mmol/L) at 12 months.

After one year, median TIR increased from 58.0% to 70.1%. HbA1c decreased from 7.6% to 7.0%. The proportion with SH decreased from 4.1% to 0.9%, and the proportion with DKA decreased from 1.2% to 0.6%. Most improvements were evident by month 3 and persisted through month 12. Only 2.8% discontinued AID during follow-up.

These findings support AID as an effective real-world strategy for improving glycemic control and reducing acute complications in T1DM.